Table 2. Crude and adjusted HR for the development of new-onset MACE.

Variables	Crude HR (95% CI) a , c	P-value	Adjusted HR (95% CI) a , b , c	P-value
ARB treatment		<0.05		<0.001
ARB(-)	1		1
ARB(+)	1.24(1.02–1.51)*		0.99(0.80–1.22)
ARB(++)	0.85(0.73–1.00)*		0.68(0.57–0.82)***
Gender		0.645		0.581
Female	1
Male	1.03(0.90–1.18)		1.04(0.91–1.19)
Age group		<0.001		<0.001
18–39	1		1
40–49	1.29(0.96–1.74)		1.18(0.87–1.59)
50–59	1.84(1.39–2.44)***		1.63(1.23–2.17)*
60–69	2.58(1.96–3.39)***		2.28(1.73–3.02)***
≥70	2.81(2.13–3.70)***		2.45(1.85–3.25)***
Comorbidity
Hypertension	1.20(1.03–1.40)	<0.05	1.12(0.94–1.33)	0.196
Diabetes	1.62(1.41–1.85)	<0.001	1.40(1.21–1.63)	<0.001
Hyperlipidemia	1.27(1.09–1.47)	<0.05	1.27(1.09–1.49)	<0.05
COPD	1.24(1.05–1.47)	<0.05	1.01(0.85–1.21)	0.888

^a HR = hazard ratio; CI = confidence interval.

^b Adjusted for gender, age group, and comorbidities.

^c *P < 0.05; ***P < 0.001.